Gland Pharma gets EIR from USFDA for Hyderabad facility

16 Jan 2025 Evaluate

Gland Pharma has received Establishment Inspection Report (EIR) from the USFDA for its Dundigal facility at Hyderabad. 

USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 22, 2024 and July 25, 2024.  The inspection was concluded with two 483 Observations.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1653.35 3.95 (0.24%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×